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Abstract
Background: Integrins are a family of transmembrane adhesion proteins that mediate cell adhesion and intracellular
signaling. Integrin-avb3 is expressed on the surface of human glioblastoma cells, and can be further induced by chemical
stress. The Arg-Gly-Asp (RGD) motif-containing peptides are specifically bound to integrin-avb3, and to inhibit
neovasculature underlying competition to normal extracellular matrix proteins. This study employed two types of RGD
peptides, cyclic RGD (c(RGDyK)) and bi-cyclic RGD (E[c(RGDyK)]2) peptide, to human glioblastoma U87MG cells with
combination of low dose Paclitaxel (PTX) pre-treatment to augment therapeutic activity for RGD peptide-induced apoptosis.
Principal Findings: Human glioblastoma U87MG cells were treated with RGD peptides in the absence or presence of initial
exposure to low-dose 10 nM PTX. Results showed that integrin-avb3 expressing on the surface of U87MG cells was induced
by 10 nM PTX pre-treatment for 12 hrs. Additionally, the U87MG cells pre-treated with PTX and followed by RGD peptides
exhibited greater expression of caspases-3, -8 and -9 than those merely treated with single agent of PTX or RGD peptide.
Furthermore, the caspase-3, -8 and -9 inhibitor presented significant protection against E[c(RGDyK)]2 peptide induced
U87MG programmed cell death. The increased expression of PTX-induced integrin-avb3 was correlated with the enhanced
apoptosis in U87MG cells.
Conclusions: This study provides a novel concept of targeting integrin-avb3 with RGD peptides in combination with low-
dose PTX pre-treatment to improve efficiency in human glioblastoma treatment.
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Introduction
Glioblastoma multiforme (GBM) is a common type of human
brain tumor composed of poorly differentiated astrocytes [1].
GBM is notorious for its highly invasive behavior and usually
responds poorly to conventional cytotoxic therapy. At present, the
therapeutic strategies for GBM include radiation therapy or
surgery in combination with anti-cancer drugs (e.g., Temozolo-
mide, Gliadel wafer, and Carmustine) [2,3]. Unfortunately,
gliomas are resistant to standard chemotherapeutic and radiation
therapeutic approaches because they exhibit infiltrative growth
patterns [4]. Therefore, the development of an optimal molecular
targeting therapy is an urgent need in GBM therapy.
Programmed cell survival or death directly relies on the
interactions between integrin receptors and extracellular matrixs
(ECMs). Integrins are a class of cell adhesion molecules that
mediate the cell-ECM interaction and regulate cell survival,
adhesion, migration, proliferation, and differentiation. The non-
covalent assembly of eighteen a and eight b subunits forms 24
integrin heterodimers [5,6]. These a and b heterodimers modulate
cellular signal transduction by forming between the extracellular
and cytoplasmic domain to dock with cytoskeleton, microfilament
associated proteins and most ECM proteins (e.g., fibronectin,
vitronectin, laminin and osteopontin) [5,7]. As a primary receptor
of cell-ECM adhesion molecules, integrin-avb3 acts as a crucial
transducer in regulating cell death signaling [7,8]. An abundance
of integrin-avb3 has been found in human malignant glioblasto-
ma, melanoma, breast tumors, metastatic prostate tumors, and
ovarian tumors [1,9]. However, the integrin-avb3 receptor protein
is not persistently expressed on various tumor cells, and is often
deficient in normal cells [10]. For example, human melanoma
A375 cells express significantly higher integrin-avb3 than human
breast cancer MDA-MB 435 cells and human prostate tumor
DU145 cells [11]. The progression of tumor invasiveness and
metastasis is positively correlated with the expression levels of
integrin-avb3 in human prostate cancer LNCaP cells [12]. When
antagonized by RGD peptides, the integrin-avb3 receptor protein
has the capability to program cell death through cell apoptosis or
neovasculacture inhibition in human glioblastoma (10 mM RGD
peptides), lung fibroblasts (0.8 mM) and breast carcinoma MCF-7
cells (1 mM) [1,13,14,15]. The RGD pentapeptide Cilengitide
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used to treat tumors by inhibiting angiogenesis in clinical phase 3
testing for GBM, and phase 1, 2 trials for metastatic squamous cell
carcinoma and advanced non-small cell lung cancer [16,17,18].
Unfortunately, the single agent of Cilengitide only has antitumor
benefit and toxicity in newly diagnosed GBM patients, but is well
tolerated in recurrent GBM patients.
Paclitaxel (PTX) is the broadest-spectrum anticancer agent
isolated from the Pacific Yew tree Taxus brevifolia, and is
currently used in the treatment of head, neck, lung, breast, ovarian
and bladder cancers [14,19]. PTX is an anticancer agent due to its
efficient induction of apoptosis. PTX interferes with microtubule
assembly by binding and stabilizing b-tubulin in the G2/M phase
of the cell cycle [14]. However, the clinical application of PTX are
usually limited by the serious side effects of drug cytotoxicity
(bruising or bleeding, anemia and peripheral neurotoxicity) and its
low aqueous solubility [14]. Therefore, this study used a low-dose
of PTX (10 nM) as a trigger to activate increased expression of
integrin-avb3 in human glioblastoma multiforme U87MG cells. In
the case of multiple myeloma, the malignant cells can express b1
integrins and utilize them to adhere to bone marrow stromal cells
promoting survival and drug resistance [20]. Lorger et al. [12]
demonstrated that the activated tumor cell integrin-avb3 supports
efficient brain metastatic growth through continuous up-regulation
of vascular endothelial growth factor protein under normoxic in
CB17/SCID mice. The increased integrin-avb3 expression is
involved in and mediates the invasion/metastasis of tumor cells
[21]. In general, normally-expressed integrin-avb3 on cells is
involved in cell-cell interactions and signal transduction. Integrin-
avb3 is highly expressed on activated endothelial cells and tumor
cells but not on quiescent cells. In the case of the later, this presents
a dichotomy, i.e., the increased expression allows for enhanced
invasiveness and metastatic potentials yet also makes the cell more
likely targets for an agent against the integrin during tumor
imaging or anti-cancer therapy [22]. In this study, the over-
expression of integrin-avb3 supplies more epitope binding sites for
improving RGD peptides binding efficiency and intervening
downstream cellular signaling.
Programmed cell death through caspase activation includes two
major pathways - the release of cytochrone c from mitochondria
(intrinsic pathway) or the ligand binding with death receptors
(extrinsic pathway) [23,24]. However, the underlying mechanism
of RGD peptide-integrin-avb3 mediated brain tumor cell death
remains unclear. Therefore, this study investigates the apoptotic
potential and the gene network of the caspase cascade in U87MG
cells undergoing RGD peptides specific-targeting to integrin-avb3
that is enhanced by low-dose PTX treatment.
Materials and Methods
Cell culture
Human glioblastoma multiforme U87MG cells (ATCC HTB-
14) were cultured in minimum essential medium with 1 nM
sodium pyruvate (Invitrogen, Carlsbad, CA) and 10% fetal bovine
serum (BSR Bio, Walkerville, Australia) in a cell incubator with
5% CO2 at 37uC.
Docking of RGD peptides
In this study, c(RGDyK) and E[c(RGDyK)]2 peptides were
individually used as an antagonist to integrin-avb3. Both
c(RGDyK) and E[c(RGDyK)]2 peptides were kindly supplied by
Dr. J. M. Lo (National Tsing Hua University, Taiwan). The
chemical structure and the docking score of RGD peptides were
shown in Fig. 1. A receptor molecular model was simulated by
docking experiment to investigate the avidity of RGD peptides to
integrin-avb3. A shape-based docking algorithm was used to fit the
RGD peptides within the integrin-avb3 receptors and conforma-
tion flexibility, and the score was provided depending on
Ligscoring function [25]. The docking protocol was described as
previous studies [25,26].
Cell treatment
The c(RGDyK) and E[c(RGDyK)]2 peptides were prepared by
DMSO in 1 mM stock. The U87MG cells (2610
5) were seeded
into 6-cm culture plate and then treated with 10 nM PTX for
12 hrs or 100 mM of c(RGDyK)/E[c(RGDyK)]2 for 24 hrs. For
some experiments, the cells were pre-treated with 10 nM PTX for
12 hrs, then washed three time with PBS and treated with 100 mM
c(RGDyK)/E[c(RGDyK)]2 for a further 24 hrs. The final
Cremophor EL and DMSO (vehicle respectively for PTX and
RGD peptides) concentration in the treated culture was ,0.1% in
the experiment and there was no vehicle effect on viability (data
not shown). The preparation of treating reagent as described in the
next paragraph.
Determination of integrin-avb3 expression
This study sought to determine if integrin-avb3 expression of
U87MG cells was altered in response to the 12 hr pre-treatment
with 10 nM PTX. Monoclonal anti-human integrin-avb3 (CD51/
61)-phycoerythrin antibody and anti-human IgG (Fc specific) were
purchased from R & D systems Inc. (Minneapolis, MN) and Sigma
(St. Louis, MO), respectively. PTX (ScinoPharm, Tainan, Taiwan)
was diluted with Cremophore EL (Sigma) for stock concentration
1 mM. Following the above-outline treatments, the U87MG cells
were washed with cold PBS for three times. The cells (1610
5) were
then incubated with 1 mg anti-human IgG for 15 min at room
temperature to block non-specific binding, then incubated in 10 ml
monoclonal anti-human integrin-avb3 (CD51/61)-phycoerythrin
antibody at 4uC for 45 min, and determined by flow cytometry
(Partect, Mu ¨nster, Germany) using WinMDI 2.8 software. The
U87MG cells incubated in 1 mg of anti-human IgG without anti-
human integrin-avb3 staining as the isotype control.
Immunofluorescence staining of integrin-avb3
U87MG cells were fixed in 4% paraformaldehyde for 10 min at
ambient temperature, and incubated in 3% bovine serum albumin
(PBST) for 30 min to block non-specific antibody binding. The
fixed U87MG cells were stained using monoclonal anti-integrin-
avb3 Ab (1:500) (Abcam, Cambridge, UK) at 4uC overnight and
1 hr incubation of anti-mouse Texas red Ab (1:500) (Abcam) in
dark. DAPI (1:1000) (Sigma) was used to localize nuclei of
U87MG cells. An Axiovert 40 CFL microscope (Carl Zeiss, St.
Louis, MO) was used to determine the signals of Texas red and
DAPI for integrin-avb3 and nuclei staining.
Viability assay
The cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma). The U87MG
cells were seeded at density of 5610
3 cells per well in a 96-well
plate and treated with a series concentration of RGD peptides (50–
200 mM). Cells were incubated in MTT (0.5 mg/ml) containing
culture medium at 37uC for 4 hrs. To each well was added 100 ml
DMSO and mixed completely to dissolve MTT. Absorbance was
measured at 570 nm with background subtraction at 650 nm by
Versamax microplate reader (Molecular devices Inc., Toronto,
Canada).
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The progression of cell cycle and apoptosis was determined by
propedium iodine (PI; Sigma) and Annexin V-FITC (Invitrogen).
The U87MG cells were harvested by trypsinization method,
washed with PBS once, and fixed by 70% cold ethanol, and
storage at 220uC for 1 hr, followed by incubation with PI/Triton
X-100/RNase A staining solution (0.1% Triton X, 0.2 mg/ml
RNase A and 20 mg/ml PI in PBS) at room temperature for
30 min. The staining cells (10,000 cells) of each sample were
detected by flow cytometry (Partect), and the percentage of cell
cycle phases and apoptosis was analyzed using FlowMax software.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was isolated from U87MG cells using RNA Trizol
(Invitrogen), and cDNA was synthesized from total RNA by a
high-capacity cDNA reverse transcription kit (Applied Biosystems
Inc.). In brief, 3 mg RNA was added 1.0 ml MultiScribe
TM reverse
transcriptase (50 unit/ml), 2.0 ml1 0 6RT random primers, 0.8 ml
206dNTP mix, 2.0 ml1 0 6RT buffer and RNase free water in a
0.2 ml PCR tube, and subsequently amplified by PCR with one
cycle of 20uC 10 min, 37uC 120 min and 85uC 5 sec.
Quantitative real time PCR
The gene expression of caspases-3, -8, -9, -10 and -12 were
determined by quantitative real-time PCR. Each 20 ml reaction
contained 6.8 ml RNase free water, 0.4 ml for each forward and
reverse primers, 0.4 ml ROX reference dye, 10 ml SYBR premix
Ex Taq (TaKaRa Bio Inc., Shiga, Japan), and 2 ml (100 ng)
template cDNA. Primers used in this study were shown in Table 1.
The cycling condition of ABI Prism 7300 real-time PCR system
(Applied Biosystems Inc.) were 50uC for 2 min, 95uC for 10 min,
and 95uC 15 sec, 55uC 30 sec, 72uC 45 sec for 40 amplification
cycles, with extension 95uC 15 sec and 60uC 1 min. The relative
level of mRNA expression was analyzed using comparative
method by SDS 1.4 software normalized to the endogenous
housekeeping gene b-actin.
Neutralized effect of caspase inhibitors on RGD-induced
apoptosis in U87MG cells pre-treated with low-dose PTX
The inhibitors of caspase-3 (Z-DEVD-FMK) (Biovision, San
Francisco, CA), caspase-8 (Z-IETD-FMK) and caspase-9 (Z-
LEHD-FMK) (R&D systems, Minneapolis, MN) were used to
determine which caspases were involved in RGD peptide-induced
apoptosis with low dose PTX pre-treatment. Caspase inhibitors
were dissolved in dimethyl sulfoxide (20 mM). U87MG cells were
Figure 1. Schematic illustration of chemical structures and docking stimulation outlining. (A, C) c(RGDyK) and (B,D) E[c(RGDyK)]2
peptides, respectively.
doi:10.1371/journal.pone.0037935.g001
Table 1. Primers used in real-time PCR analysis.
Gene Sense primer (59R39) Anti-sense primer (59R39)
Caspase 3 TGGTTCATCCAGTCGCTTTGT AATTCTGTTGCCACCTTTCGG
Caspase 8 AAAAGCAAACCTCGGGATAC CCAAGTGTGTTCCATTCCTGTC
Caspase 9 TGGACATTGGTTCTGGAGGATT CACGGCAGAAGTTCACATTGTT
Caspase 10 GGCTATGTATCCTTTCGGCA CCCTGTTTGTCCACTCTTCG
Caspase 12 GCCTCAACATCCGCAACAA ATCTCACATCCCCAAAAGGTC
doi:10.1371/journal.pone.0037935.t001
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5 cells/ml and pre-incubated with 10 mM caspase
inhibitor for 3 hrs followed by 12 hr 10 nM PTX pre-treatment
and 24 hr E[c(RGDyK)]2 peptide. The same amount of DMSO as
treatment groups was used in the control group. Three indepen-
dent experiments were performed for determination of caspase
gene expression.
Statistical analysis
Results were obtained through at least three separate experi-
ments. Data are reported as means 6 SD. All statistical analysis
was conducted by Microsoft Excel Statistic Suit. Statistically
significant differences among groups were determined using
Student’s t test (p,0.05).
Results
RGD peptide docking simulation
This study assessed the interaction of RGD peptides with
integrin-avb3 through the docking simulation performing on the
Discovery Studio 1.6 environment. Results showed that the scores
of docking simulation were 296.04 and 245.89 for c(RGDyK) and
E[c(RGDyK)]2 peptides, respectively (Fig. 1). The output conver-
gent conformations demonstrated that the RGD peptides used in
this study had reliable binding affinity towards the integrin
interface.
PTX induced expression of integrin-avb3
The expression of integrin-avb3 on U87MG cell surface was
determined using flow cytometry with anti- integrin-avb3
antibody. U87MG cells exposed to 10 nM PTX for 12 hr had a
significant enhanced expression of integrin-avb3 (Fig. 2A). To
examine whether low-dose 10 nM PTX treatment induced
integrin-avb3 over-expression, the immunofluorescent detection
of integrin-avb3 and DAPI (49,6-diamidino-2-phenylindole) stain-
ing were performed. The results in Fig. 2B(IV-VI) showed that
integrin-avb3 was induced by 10 nM PTX and localized around
the cell membrane. The U87MG cells were incubated
E[c(RGDyK)]2 peptide at 37uC and then treated with 10 nM
PTX to evidence RGD peptide antagonized PTX-induced
integrin-avb3 epitope. The result showed U87MG cells were
entirely blocked by RGD peptide that meant the RGD peptide
was specific binding to integrin-avb3 binding (Fig. 2B(VII–IX)).
Cytotoxic and apoptotic effects of PTX and RGD peptides
on U87MG cells
The results of the MTT assay indicated that c(RGDyK)/
E[c(RGDyK)]2 (0, 40, 80, 100, 150, 200 mM) had no cytotoxicity
to U87MG cells (Fig. 3A and 3B). This study used low-dose PTX
to induce over-expression of integrin-avb3. Cell viability of
U87MG cells was decreased after 12 hr 10 nM PTX pre-
treatment and following exposure to 100 mM c(RGDyK)/
E[c(RGDyK)]2 peptides for 24 hrs (Fig. 3A and 3B). According
to the results of cell viability using the MTT assay, the predictive
LD50 of PTX in this study was higher than 100 nM (Fig. 3C). The
applied low-dose of 10 nM PTX for 12 hr had no effect on cell
death in U87MG cells (Fig. 3C). The apoptotic percentage of
U87MG cells pre-treated with 10 nM PTX for 12 hr and then
100 mM c(RGDyK)/E[c(RGDyK)]2 for 24 hr was higher than
those with 24 hr c(RGDyK)/E[c(RGDyK)]2 treatment alone (69.5
[60.8%] vs. 39.5 [60.6%], Fig. 4A; 87.9 [61.3%] vs. 26.2
[60.9%], Fig. 4B).
Gene expression of caspase signaling regulated by PTX
and RGD peptide
This study applies low-dose PTX and RGD peptide to mediate
the programmed brain tumor cell death, and further investigated
the reconstruction of caspase gene network. The results of real-
time PCR showed that the dose of 10 nM PTX induced the
augment expression of caspase-3, -8, -9, -10 and -12 genes (Fig. 5).
Exposure of the U87MG cells to to 40 mM c(RGDyK) peptide
following a 10 nM PTX pre-treatment increased the expression of
caspase-3, -8 and -9 compared to that seen following treatment
with 10 nM PTX alone (fold-changes respectively of: caspase-
3=2.4 [60.1] vs. 1.5 [60.02], respectively; caspase-8=1.5
[60.2] vs. 1.0 [60.1]; and caspase-9=3.1 [60.3] vs. 3.4
[60.02]). The mRNA expression of caspase-3, -8, and -9 achieved
2.7 [60.1] vs. 1.5 [60.02], 2.4 [60.1] vs. 1.0 [60.1], and 5.0
[60.4] vs. 3.4 [60.02] -fold changes in response to the exposure of
40 mM E[c(RGDyK)]2 peptide with 10 nM PTX pre-treatment
that compared to 10 nM of PTX single agent treatment,
respectively. Definitely, the E[c(RGDyK)]2 peptide was more
efficient to cause apoptosis for U87MG cells underlying its double
side wing structure. Furthermore, to determine whether the
changed expression of caspase genes was underwent programmed
apoptosis, the specific inhibitors of caspase-3, -8 and -9 were used
to elucidate this extrinsic caspase pathway. The expression of
caspase-3, -8, and -9 genes was apparently suppressed in U87MG
cells pre-incubated with, respectively, Z-DEVD-FMK, Z-IETD-
FMK and Z-LEHD-FMK, and then underwent the 10 nM PTX
and 40 mM E[c(RGDyK)]2 peptide treatment regimen (Fig. 6; fold
change w/o vs. with inhibitor: 3.9 [60.2] vs. 1.4 [60.5] for
caspase-3, 2.4 [60.3] vs. 1.4 [60.4] for caspase-8, 5.9 [60.4] vs.
1.1 [60.3] for caspase-9).
Discussion
This study used low-dose PTX to activate inegrin-avb3
expression and antagonized to RGD peptides for programmed
cell death. The two RGD peptides, c(RGDyK) and
E[c(RGDyK)]2, used in this study have the affinity for integrin-
avb3. The docking simulation showed that c(RGDyK) peptide
had higher avidity to integrin-avb3 than E[c(RGDyK)]2 peptide.
This might be due to the stereo structure of E[c(RGDyK)]2
peptide, which consists of two side wings to neutralize the total
docking score. The two side wings of E[c(RGDyK)]2 peptide
provided better flexibility to attach integrin-avb3 expressing in
U87MG cells. The results of MTT assay showed that
E[c(RGDyK)]2 peptide had greater cytotoxicity than c(RGDyK)
peptide. Additionally, as expected, E[c(RGDyK)]2 was more
efficient in activating caspase signaling for programmed cell death
than c(RGDyK) peptide.
Tumoricidal agents such as methylating procarbazine, chlor-
oethylating BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; carmus-
tine), and CCNU (1-(2-chloroethyl)-3-chlohexyl-1-nitrosourea;
lomustine) have been used in the clinical treatment of human
brain tumors [27]. Nonetheless, the outcome remains restricted
due to the DNA repair activities and the drug efflux system as
inferred from the presence of P-glycoprotein in brain capillaries
[28]. Thus, this study used PTX as an anticancer agent to avoid
possible interference with inertia genotype. PTX-induced pro-
grammed cell death is directed by death receptor ligand binding
(e.g. Fas-associated death domain protein; FADD), cell cycle
interventions, and characteristic p53-independent [14,29]. In the
past two decades, there have been various medical advancements
in drug innovation and treatment methods. Several novel agents
targeting DNA base pair for disrupting tumorgenesis of glioblas-
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peptides can specifically bind to integrin-avb3 in tumor cells but
not in normal tissue cells [30,31]. However, therapeutic targeting
strategies are usually restricted by the amount of substance
(receptor) for ligand (peptide drug) attachment and the influence of
non-targeting cells to confine cytotoxicity efficiency toward tumor
cells.
This study examined the role of integrin-avb3 in response to
low-dose (10 nM) PTX using the brain tumor U87MG cell line
model. The cell surface expression of integrin-avb3 increased
dramatically in U87MG cells pre-treated with 10 nM PTX for
12 hr compared to those in the control group. This integrin
clustering effect was due to the reorganization of actin filament
into large stress fibers as the inside-out signaling [7]. PTX is often
used against various tumors in clinical applications. However, the
dosimetry studies of PTX used to treat human brain cancer
derived cell lines with a wide tolerant range which depends on the
duration and concentration of PTX exposure [32]. The LD90 of
PTX is defined 250–300 nM for 1 hr treatment in human
glioblastoma brain tumor [14,33]. In this study, low-dose
(10 nM) PTX was not used directly to program cell death but
acted as a stressor to increase the expression of integrin-avb3o n
cell membranes. As shown in Fig. 2A and 2B (IV), integrin-avb3o f
U87MG cells were likely to be induced after 12 hrs 10 nM PTX
treatment. Moreover, the results of immunostaining in this study
showed U87MG cells were entirely blocked by E[c(RGDyK)]2
Figure 2. Expression of surface integrin-avb3 in U87MG cells with the treatment of 10 nM PTX. (A) Cytometric analysis of the expression
of integrin-avb3 was determined by specific integrin-avb3 antibody staining. The expression of integrin-avb3 in U87MG cells treated with 10 nM PTX
for 12 hrs was higher than control group. (B) Immunofluorescent detection of integrin-avb3 and nuclei was respectively stained by anti-integrin-avb3
antibody (Texas red) and DAPI (blue). Integrin-avb3 was obviously localized in the cell periphery. (I-III) indicated the U87MG cell isotypic control
group. (IV-VI) Integrin-avb3 of U87MG cells was induced after 12 hr 10 nM PTX. (VII–IX) U87MG cells were pre-incubated with E[c(RGDyK)]2 peptide to
antagonized PTX-induced integrin-avb3 expression.
doi:10.1371/journal.pone.0037935.g002
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avb3 binding (Fig. 2B(IX)). From the basis studies using electron
microscopy, NMR, FRET (Fo ¨rster resonance energy transfer) and
crystallography, integrins appearing the bent conformation and
low affinity state are determined as the inactive form [34,35]. The
increased integrin-avb3 complexes can form catch bonds (become
strengthened) under further stimulation that is induced from the
extracellular or intracellular end of molecules [36,37]. This natural
rising phenomenon suggested the opportunity to solve the
deficiency of integrin-avb3 in various tumor cells thereby
improving therapeutic effect. The results of flow cytometry
showed that U87MG cells treated with 10 nM PTX (29.93%)
Figure 3. Cytotoxicity of U87MG cells treated with RGD peptide or the combination of PTX and RGD peptide was quantified using
MTT assay. (A) Cell viability of c(RGDyK) peptide or combination pre-treated by 10 nM PTX in U87MG cells. (B) Cell viability of E[c(RGDyK)]2 peptides
or combination pre-treated by 10 nM PTX in U87MG cells. Cell viability was decreased at 100 mM c(RGDyK) or E[c(RGDyK)]2 peptide. (C) Cell viability of
a serial concentration of PTX for 24 hr in U87MG cells. The results of triplicate experiments are expressed as mean 6 standard deviation.
doi:10.1371/journal.pone.0037935.g003
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control group (19.45%) (data not shown). This confirmed the
mitotic inhibition characteristics of low-dose PTX (10–100 nM) in
an arrest at G2/M phase of the cell cycle [6].
Previous studies explored the mechanisms through which
integrin mediates cell death showing that the induced apoptosis
is correlated to the subcellular localization of activated caspase
cascade [1,5,33]. Based on their homology in amino acid
sequence, the initiator caspase signaling molecules caspase-8 and
-9, are responsible for activation of caspase cascade and to induce
the effector caspase-3 for the actual execution of apoptosis (so-
called extrinsic pathway) [38]. In this study, in the presence of
40 mM RGD peptide in U87MG cells, the mRNA levels of
caspase-3, -8 and -9 exhibited up to 3.5-fold increase. These
caspase cascades were involved in death receptor-mediated
pathways. Previous studies showed that blocking integrin-avb3
via RGD peptides induces cell death in human endothelial cells
through activation of caspase-3, -8 and -9, FADD (Fas-Associated
protein with Death Domain), tumor necrosis factor-a and TRAIL
(TNF related apoptosis inducing ligand) pathways and is
correlated to the down-regulation of FAK (focal adhesion kinase)
expression in tumor cells [39,40]. In addition, the RGD sequence
contains the large subunit of caspase-3 and the small subunit of
caspase-8, beginning at positions R144 and R435, respectively
[41]. The equivalent dosage of PTX in clinical applications
required to induce apoptosis depends on the release of cytochrome
c from mitochondrial (intrinsic pathway) or the activation of
caspase-10 and -12, and their downstream signaling pathways
caspase-6, -8 and -3 [14,19,42,43]. In addition, the low-dose PTX
induced cell cycle arrest and suppressed the dynamics of
microtubule in U87MG cells, which facilitated the activation of
caspase-10 and -12, and promoted the following caspase cascade.
Caspase-10 and -12 played an essential role of initiator in
apoptosis by PTX pre-treatment. The viability assay in this study
suggested that there was no cytotoxicity effect up to 200 mMo f
RGD peptide in a single treatment, but the decreased cell viability
appeared at 100 mM RGD peptide exposure after 10 nM PTX
pre-treatment. These results suggested that the RGD peptide
alone was not sufficient enough to induce cell apoptotic responses
immediately, but the combination of 40 mM RGD peptide with
10 nM PTX led to the up-regulation of caspase-3, -8, and -9 for
the apoptotic process. In a brief summary, U87MG cells pre-
treated wiht 10 nM PTX following with treatment of 40 mM RGD
peptide potentially boost for programmed cell apoptosis than
10 nM PTX or 40 mM RGD peptide treatment alone. Further-
more, for U87MG cells exposed to E[c(RGDyK)]2 with 10 nM
Figure 4. Cytometric analysis of apoptosis events in U87MG cells treated with PTX, c(RGDyK)/E[c(RGDyK)]2 peptides or the
combination of PTX and c(RGDyK)/E[c(RGDyK)]2 peptides. Determination of apoptosis was using Annexin-V-FITC staining and FACS detector.
The occurrence of programmed apoptosis was obviously in U87MG cells pre-treated with 10 nM PTX followed by 100 mM (A) c(RGDyK)/(B)
E[c(RGDyK)]2 peptides. Triplicate experiments were obtained for analysis.
doi:10.1371/journal.pone.0037935.g004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37935PTX pre-treatment showed the efficiency for up-regulation
caspase genes -3, -8 and -9 than cells exposed to c(RGDyK)
combined 10 nM pre-treatment (E[c(RGDyK)]2+PTX vs.
c(RGDyK)+PTX caspase-3=2.7 [60.1] vs. 2.4 [60.1], respec-
tively; caspase-8=2.4 [60.1] vs. 1.5 [60.2]; and caspase-9=5.0
[60.4] vs. 3.1 [60.3]).
In Fig. 6, gene expression of caspase-3 and caspase-8 was
increased after the treatment of 10 nM PTX and 40 mM RGD,
and caspase-3 was suppressed when it was supplied with caspase-3
or caspase-8 inhibitors. But caspase 8 only was suppressed with
caspase-8 inhibitor as well as caspase 9 suppressed with caspase-9
inhibitor neither caspase-3 nor -8 inhibitors. The results of
inhibitor neutralized experiment showed that caspase-9 was at the
upstream of caspase-8 and -3, and caspase-8 up-regulated caspase-
3 undelying the PTX and RGD peptide-induced programmed cell
death. The experiments of Fig. 5 and Fig. 6 were not achieved at
the same time. Although the values are various among the same
treatments, the patterns of fold-change in caspase expression were
similar in comparison with control group. Most importantly, this
study used 10 nM PTX as a biophysics stressor to modulate
Figure 5. Quantitative expression of caspase genes in U87MG cells treated with PTX, c(RGDyK)/E[c(RGDyK)]2 peptides or the 12 hr
PTX pre-treatment following with c(RGDyK)/E[c(RGDyK)]2 peptides exposure. U87MG cells were treated with 40 mM c(RGDyK)/
E[c(RGDyK)]2 peptides for 24 hrs with or without 10 nM PTX pre-treatment for 12 hrs. The mRNA expression of (A) caspase-3, (B) caspase-8, (C)
caspase-9, (D) caspase-10, and (E) caspase-12 was determined using real-time PCR. The increased levels of caspases -3, -8 and -9 were apparent in the
pre-treatment with PTX for 12 hrs and 24 hr 40 mM c(RGDyK)/E[c(RGDyK)]2 peptides. (fold changes of caspases -3, -8 and -9; PTX+c(RGDyK) vs. PTX
alone: caspase-3=2.4 [60.1] vs. 1.5 [60.02], caspase-8=1.5 [60.2] vs. 1.0 [60.1], and caspase-9=3.1 [60.3] vs. 3.4 [60.02]; PTX+E[c(RGDyK)]2 vs. PTX
alone: caspase-3=2.7 [60.1] vs. 1.5 [60.02], caspase-8=2.4 [60.1] vs. 1.0 [60.1], and caspase-9=5.0 [60.4] vs. 3.4 [60.02]). The bars are represented
the mean fold change of at least three independent experiments. Asterisk indicates significant at p,0.05 compared with 10 nM PTX alone.
doi:10.1371/journal.pone.0037935.g005
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cells. The up-regulation of integrin-avb3 had a potent binding
effect on RGD peptides, which competed with matrix molecules
and activated programmed cell death during apoptosis. These data
offered additional evidence that the up-regulation of integrin-avb3
expression increased RGD peptide-induced programmed cell
death. In summary, a low dose of 10 nM PTX pre-treatment
aroused caspase-10, and the activation of caspase-12 hinged on the
up-regulation of integrin-avb3 in programmed cell death progress
to subsequently stimulate the activation of caspase-9, -8 and
caspase-3. Fig. 7 shows the apoptotic pathway of the combination
treatment.
Figure 6. Neutralized effect of caspase-3, -8 and -9 inhibitors on the caspase mRNA expression induced by PTX pre-treatment and
E[c(RGDyK)]2 peptide. U87MG cells were respectively pre-incubated with inhibitors of caspase-3 (Z-DEVD-FMK), caspase-8 (Z-IETD-FMK) or
caspase-9 (Z-LEHD-FMK) and followed by 10 nM PTX pre-treatment for 12 hr and 40 mM E[c(RGDyK)]2 treatment for 24 hr. The mRNA expression of
(A) caspase-3, (B) caspase-8, (C) caspase-9, (D) caspase-10, and (E) caspase-12 was determined using real-time PCR. Eventually, either caspase-3, -8 or -
9 inhibitor effectively to suppress the expression of caspase-3, -8 and -9. Asterisk indicates significant at p,0.05 compared with 10 nM PTX alone.
doi:10.1371/journal.pone.0037935.g006
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37935Conventional cancer treatments have matured into an effective
means for tumor killing in various forms. Even though human
glioblastoma U87MG cells are resistant to chemotherapy, there
are many methods to destroy human glioblastoma cancer through
different cellular mechanisms. The drawbacks of target-specific
cancer therapy include the short-lived nature and limited amount
of target receptors in tumor cells, which limit therapeutic options
and prognoses. Previous studies showed the natural amount of
integrin-avb3 expressed in various tumor cell membranes, and
developed the delivery carriers (liposomes, micelles, nanoparticles)
of RGD peptide or its analogue synthesis [44]. The results of this
study showed that human glioblastoma U87MG cells expressed
integrin-avb3, were up-regulated by a pre-treatment of low-dose
PTX, and underwent programmed cell death through the
activation of caspase-3, -8, -9, -10 and -12. The signal transduction
of integrin-avb3 correlates to the level of its expression in cells,
which can exert through a chemo-drug induction. Further studies
should investigate the adjuvant targeting therapeutic strategy in
integrin-avb3 mediated cellular signaling to determine the
naturally occurring integrin-avb3 in a variety of cancer cells and
ideal stress dosage for its up-regulation.
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